Morgan Stanley lowered the firm’s price target on WW (WW) to $34.50 from $38 and keeps an Equal Weight rating on the shares. Early reads in diet season show strong top of funnel performance, implying WW’s new marketing and programs are drawing consumer interest, but that doesn’t yet appear to have translated to subscriber growth as app downloads have decelerated through diet season, the analyst tells investors.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WW:
- Weight Watchers expands GLP-1 platform with access to Wegovy pill
- Balanced View on WW: Seasonal Upside and New Program Optionality Tempered by Execution Risk Supporting Hold Rating
- WW introduces fully integrated GLP-1 platform
- Novo launches introductory self-pay offer for Wegovy, Ozempic for $199 per month